

Oncology Nursing™

U P D A T E

Clinical Investigator and Nursing Perspectives
on the Management of Common Cancers

FACULTY INTERVIEWS

David R Spigel, MD

Beth Eaby-Sandy, MSN, CRNP, OCN

EDITOR

Neil Love, MD

**LUNG CANCER
EDITION**



Oncology Nursing Update Lung Cancer Edition

A Continuing Nursing Education Audio Series

OVERVIEW OF ACTIVITY

Lung cancer is one of the most rapidly evolving fields in oncology nursing and is a major public health concern, with more than 228,000 new cases and 160,000 deaths from metastatic lung cancer estimated to have occurred in the United States during 2013. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with lung cancer, the *Oncology Nursing Update* audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with lung cancer. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with lung cancer.

PURPOSE STATEMENT

To present the most current research developments in lung cancer and to provide the perspectives of a nurse practitioner and clinical investigator on the diagnosis and treatment of lung cancer.

LEARNING OBJECTIVES

- Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of lung cancer, including tyrosine kinase inhibitors (TKIs), chemotherapy regimens and targeted biologic treatments.
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
- Establish an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced non-small cell lung cancer (NSCLC).
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with lung cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CREDIT DESIGNATION STATEMENT

This educational activity for 1.2 contact hours is provided by Research To Practice during the period of February 2014 through February 2015.

FOR SUCCESSFUL COMPLETION

This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website **ResearchToPractice.com/ONULung114** also includes links to relevant abstracts and full-text articles.

To receive credit, participants should read the learning objectives and faculty disclosures, listen to the CD and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at **ResearchToPractice.com/ONULung114/CNE**. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 75% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

This activity is supported by educational grants from Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation and Genentech BioOncology.

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

If you would like to discontinue your complimentary subscription to *Oncology Nursing Update*, please email us at **Info@ResearchToPractice.com**, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

CNE INFORMATION

Oncology Nursing™

U P D A T E

FACULTY AFFILIATIONS



David R Spigel, MD
Program Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee



**Beth Eaby-Sandy, MSN,
CRNP, OCN**
Nurse Practitioner
Outpatient Thoracic Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

EDITOR



Neil Love, MD
Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Spigel** — Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. **Ms Eaby-Sandy** — Consulting Agreements: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Speakers Bureau: Amgen Inc, Genentech BioOncology, Lilly.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

SELECT PUBLICATIONS

Cappuzzo F et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol* 2010;11(6):521-9.

Ciuleanu T et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. *Lancet* 2009;374(9699):1432-40.

Hashemi-Sadraei N, Pennell NA. Advanced non-small cell lung cancer (NSCLC): Maintenance therapy for all? *Curr Treat Options Oncol* 2012;13(4):478-90.

Janjigian YY et al. Activity of afatinib/cetuximab in patients (PTS) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. *Proc ESMO* 2012; **Abstract 12270**.

Lynch TJ et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. *Oncologist* 2007;12(5):610-21.

Oxnard GR et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. *Clin Cancer Res* 2011;17(17):5530-7.

Patel JD et al. A randomized, open-label, Phase 3, superiority study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (pts) with stage IIIB or IV non-squamous non-small cell lung cancer (NS-NSCLC). *ASTRO* 2012; **Abstract LBPL1**.

Paz-Ares LG et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2013;31(23):2895-902.

Paz-Ares L et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. *Lancet Oncol* 2012;13(3):247-55.

Pirker R et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. *Lancet Oncol* 2012;13(1):33-42.

Pirker R et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. *Lancet* 2009;373(9674):1525-31.

Ricciardi S et al. Toxicity of targeted therapy in non-small-cell lung cancer management. *Clin Lung Cancer* 2009;10(1):28-35.

Saif MW et al. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. *JOP* 2008;9(3):267-74.

Sequist LV et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol* 2013;31(27):3327-34.

Socinski MA et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. *Ann Oncol* 2013;24(9):2390-6.

Socinski MA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. *J Clin Oncol* 2012;30(17):2055-62.

Spigel DR et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2013;31(32):4105-14.

Spigel DR et al. **Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAB or placebo in combination with erlotinib in advanced NSCLC.** *Proc ASCO* 2011;**Abstract 7505**.

Wu YL et al. **LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.** *Proc ASCO* 2013;**Abstract 8016**.

Yang JC et al. **Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.** *J Clin Oncol* 2013;31(27):3342-50.

Yang JC et al. **LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.** *Proc ASCO* 2012;**Abstract LBA7500**.

QUESTIONS (PLEASE CIRCLE ANSWER):

- Which of the following is an irreversible EGFR TKI?
 - Gefitinib
 - Erlotinib
 - Afatinib
 - None of the above
- Which of the following EGFR TKIs is approved by the FDA for the treatment of lung cancer?
 - Afatinib
 - Erlotinib
 - Both a and b
- Which of the following side effects is of concern when counseling patients with NSCLC who are about to initiate treatment with erlotinib?
 - Alopecia
 - Mild diarrhea
 - Rash
 - Both b and c
- Cetuximab in combination with afatinib has demonstrated significant responses in patients with EGFR-mutant, metastatic NSCLC with acquired resistance to EGFR TKIs.
 - True
 - False
- Evaluation of *nab* paclitaxel in combination with carboplatin versus standard-formulation paclitaxel in combination with carboplatin in patients with advanced squamous cell carcinoma of the lung indicated _____ in patients who received *nab* paclitaxel/carboplatin.
 - Greater efficacy, improved tolerability
 - Similar efficacy, similar tolerability
 - Less efficacy, improved tolerability
- The monoclonal antibody onartuzumab is a(n) _____.
 - EGFR inhibitor
 - KRAS inhibitor
 - MET inhibitor
- Which of the following are potential contraindications to the use of bevacizumab?
 - Squamous cell histology
 - Hemoptysis
 - Severe hypertension
 - Recent myocardial infarction
 - Recent stroke
 - All of the above
- Management strategies for the dermatologic toxicities associated with EGFR TKI use include _____.
 - Oral antibiotics
 - Topical clindamycin
 - Hydrocortisone cream
 - Erlotinib dose reduction or discontinuation
 - All of the above

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Existing and emerging clinical strategies to prevent and manage EGFR TKI-associated dermatotoxicities	4 3 2 1	4 3 2 1
Comparative toxicity with weekly <i> nab </i> paclitaxel versus standard-formulation paclitaxel	4 3 2 1	4 3 2 1
Recent FDA approval of afatinib and integration into clinical treatment algorithms	4 3 2 1	4 3 2 1
Contraindications to the use of bevacizumab in patients with metastatic NSCLC	4 3 2 1	4 3 2 1

Has the activity unfairly influenced you toward a particular product or service?

Yes No

If yes, please describe what was presented:

Will this activity help you improve patient care?

Yes No Not applicable

If yes, how will it help you improve patient care?

Did the activity meet your educational needs and expectations?

Yes No

If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of lung cancer, including tyrosine kinase inhibitors (TKIs), chemotherapy regimens and targeted biologic treatments.4 3 2 1 N/M N/A
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.4 3 2 1 N/M N/A
- Establish an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced non-small cell lung cancer (NSCLC).4 3 2 1 N/M N/A
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with lung cancer.4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

What other practice changes will you make or consider making as a result of this activity?

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

- Yes, I am willing to participate in a follow-up survey.
No, I am not willing to participate in a follow-up survey.

PART 2 — Please tell us about the faculty and editor for this educational activity

Table with 4 columns: 4 = Excellent, 3 = Good, 2 = Adequate, 1 = Suboptimal. Rows include Faculty (David R Spigel, MD; Beth Eaby-Sandy, MSN, CRNP, OCN) and Editor (Neil Love, MD) with ratings for Knowledge of subject matter and Effectiveness as an educator.

Please recommend additional faculty for future activities:

Other comments about the faculty and editor for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: Specialty:

Professional Designation:

- MD DO PharmD NP CNS RN
PA Other

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

Signature: Date:

The expiration date for this activity is February 2015. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/ONULung114/CNE.

Oncology Nursing™

U P D A T E

Editor	Neil Love, MD
Director, Clinical Content and CPD/CME	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Editorial	Clayton Campbell Marilyn Fernandez, PhD Gloria Kelly, PhD Kemi Obajimi, PhD Margaret Peng
Creative Manager	Fernando Rendina
Graphic Designers	Tamara Dabney Silvana Izquierdo
Managing Editor	Kirsten Miller
Senior Production Editor	Aura Herrmann
Copy Editors	Margo Harris Rosemary Hulce Pat Morrissey/Havlin Alexis Oneca
Production Manager	Tracy Potter
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Faculty Relations Manager	Lisa Suarez
Continuing Education Administrator for Nursing	Karen Gabel Speroni, BSN, MHSA, PhD, RN
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com
For CME/CNE Information	Email: CE@ResearchToPractice.com

Copyright © 2014 Research To Practice. All rights reserved.

The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the

newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Oncology Nursing™

U P D A T E

Copyright © 2014 Research To Practice.

This activity is supported by educational grants from
Astellas, Boehringer Ingelheim Pharmaceuticals Inc,
Celgene Corporation and Genentech BioOncology.

Research To Practice®

Sponsored by Research To Practice.

Last review date: February 2014

Release date: February 2014

Expiration date: February 2015

Contact hours: 1.2